4,002 reports of this reaction
10.5% of all DABRAFENIB reports
#1 most reported adverse reaction
PYREXIA is the #1 most commonly reported adverse reaction for DABRAFENIB, manufactured by Novartis Pharmaceuticals Corporation. There are 4,002 FDA adverse event reports linking DABRAFENIB to PYREXIA. This represents approximately 10.5% of all 37,967 adverse event reports for this drug.
Patients taking DABRAFENIB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is a frequently reported adverse event for DABRAFENIB, accounting for a significant proportion of all reports.
In addition to pyrexia, the following adverse reactions have been reported for DABRAFENIB:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 4,002 FDA reports for DABRAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 10.5% of all adverse event reports for DABRAFENIB, making it one of the most commonly reported side effect.
If you experience pyrexia while taking DABRAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.